Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Terrence N. Wong, Giridharan Ramsingh, Andrew L. Young, Christopher A. Miller, Waseem Touma, John S. Welch, Tamara L. Lamprecht, Dong Shen, Jasreet Hundal, Robert S. Fulton, Sharon Heath, Jack D. Baty, Jeffery M. Klco, Li Ding, Elaine R. Mardis, Peter Westervelt, John F. Dipersio, Matthew J. Walter, Timothy A. Graubert, Timothy J. LeyTodd E. Druley, Daniel C. Link, Richard K. Wilson

Research output: Contribution to journalArticlepeer-review

499 Scopus citations


Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy. There are several features that distinguish t-AML from de novo AML, including a higher incidence of TP53 mutations, abnormalities of chromosomes 5 or 7, complex cytogenetics and a reduced response to chemotherapy. However, it is not clear how prior exposure to cytotoxic therapy influences leukaemogenesis. In particular, the mechanism by which TP53 mutations are selectively enriched in t-AML/t-MDS is unknown. Here, by sequencing the genomes of 22 patients with t-AML, we show that the total number of somatic single-nucleotide variants and the percentage of chemotherapy-related transversions are similar in t-AML and de novo AML, indicating that previous chemotherapy does not induce genome-wide DNA damage. We identified four cases of t-AML/t-MDS in which the exact TP53 mutation found at diagnosis was also present at low frequencies (0.003-0.7%) in mobilized blood leukocytes or bone marrow 3-6 years before the development of t-AML/t-MDS, including two cases in which the relevant TP53 mutation was detected before any chemotherapy. Moreover, functional TP53 mutations were identified in small populations of peripheral blood cells of healthy chemotherapy-naive elderly individuals. Finally, in mouse bone marrow chimaeras containing both wild-type and Tp53+- haematopoietic stem/progenitor cells (HSPCs), the Tp53+- HSPCs preferentially expanded after exposure to chemotherapy. These data suggest that cytotoxic therapy does not directly induce TP53 mutations. Rather, they support a model in which rare HSPCs carrying age-related TP53 mutations are resistant to chemotherapy and expand preferentially after treatment. The early acquisition of TP53 mutations in the founding HSPC clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemotherapy that are typical of patients with t-AML/t-MDS.

Original languageEnglish (US)
Pages (from-to)552-555
Number of pages4
Issue number7540
StatePublished - Feb 26 2015

Bibliographical note

Funding Information:
Acknowledgements We thank A. Schmidt, B. McKethan and R. Miller for technical assistance, and K. Odell and J. Tucker-Davis for animal care. We thank P. Goodfellow and J. Ivanovich for providing peripheral blood leukocyte genomic DNA from cancer-free individuals.This work was supported byNationalInstitutes ofHealth grants PO1 CA101937 (D.C.L.) and U54 HG003079 (R.K.W.) and by a grant from the Leukemia & Lymphoma Society (D.C.L.).

Publisher Copyright:
© 2015 Macmillan Publishers Limited. All rights reserved.


Dive into the research topics of 'Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this